a phase ii multicenter evaluation of cisplatin ( 90 mg/m2 , day 1 ) and etoposide ( 150 mg/m2 , days 2 , 3 , and 4 ) in 4-week cycles was carried out in 21 relapsed children with rhabdomyosarcoma ( rms ) and six with non-rms soft tissue sarcomas ( nrsts ) .
C0015133
etoposide
C0035412
rhabdomyosarcoma